BACKGROUND & AIMS: The corticotrophin-releasing hormone (CRH) family of peptides modulates intestinal inflammation and the CRH receptor 2 (CRHR2) suppresses postnatal angiogenesis in mice. We investigated the functions of CRHR1 and CRHR2 signaling during intestinal inflammation and angiogenesis. METHODS: The activities of CRHR1 and CRHR2 were disrupted by genetic deletion in mice or with selective antagonists. A combination of in vivo, ex vivo, and in vitro measures of angiogenesis were used to determine their activity. CRHR1(-/-) mice and CRHR2(-/-) mice with dextran sodium sulfate-induced colitis were analyzed in comparison with wild-type littermates (controls). RESULTS: Colitis was significantly reduced in mice in which CRHR1 activity was disrupted by genetic deletion or with an antagonist, determined by analyses of survival rate, weight loss, histological scores, and cytokine production. Inflammation was exacerbated in mice in which CRHR2 activity was inhibited by genetic deletion or with an antagonist, compared with controls. The inflamed intestines of CRHR1(-/-) mice had reduced microvascular density and expression of vascular endothelial growth factor (VEGF)-A, whereas the intestines of CRHR2(-/-) mice had increased angiogenesis and VEGF-A levels. An antagonist of VEGFR2 activity alleviated colitis in CRHR2(-/-) mice. Ex vivo aortic vessel outgrowth was reduced when CRHR1 was deficient but increased when CRHR2 was deficient. The CRHR1 preferred agonist CRH stimulated tube formation, proliferation, and migration of cultured intestinal microvascular endothelial cells by phosphorylating Akt, whereas the specific CRHR2 agonist Urocortin III had opposite effects. CONCLUSION: CRHR1 promotes intestinal inflammation, as well as endogenous and inflammatory angiogenesis whereas CRHR2 inhibits these activities. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS: The corticotrophin-releasing hormone (CRH) family of peptides modulates intestinal inflammation and the CRH receptor 2 (CRHR2) suppresses postnatal angiogenesis in mice. We investigated the functions of CRHR1 and CRHR2 signaling during intestinal inflammation and angiogenesis. METHODS: The activities of CRHR1 and CRHR2 were disrupted by genetic deletion in mice or with selective antagonists. A combination of in vivo, ex vivo, and in vitro measures of angiogenesis were used to determine their activity. CRHR1(-/-) mice and CRHR2(-/-) mice with dextran sodium sulfate-induced colitis were analyzed in comparison with wild-type littermates (controls). RESULTS:Colitis was significantly reduced in mice in which CRHR1 activity was disrupted by genetic deletion or with an antagonist, determined by analyses of survival rate, weight loss, histological scores, and cytokine production. Inflammation was exacerbated in mice in which CRHR2 activity was inhibited by genetic deletion or with an antagonist, compared with controls. The inflamed intestines of CRHR1(-/-) mice had reduced microvascular density and expression of vascular endothelial growth factor (VEGF)-A, whereas the intestines of CRHR2(-/-) mice had increased angiogenesis and VEGF-A levels. An antagonist of VEGFR2 activity alleviated colitis in CRHR2(-/-) mice. Ex vivo aortic vessel outgrowth was reduced when CRHR1 was deficient but increased when CRHR2 was deficient. The CRHR1 preferred agonist CRH stimulated tube formation, proliferation, and migration of cultured intestinal microvascular endothelial cells by phosphorylating Akt, whereas the specific CRHR2 agonist Urocortin III had opposite effects. CONCLUSION:CRHR1 promotes intestinal inflammation, as well as endogenous and inflammatory angiogenesis whereas CRHR2 inhibits these activities. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: Tracy L Bale; Frank J Giordano; Reed P Hickey; Yan Huang; Anjali K Nath; Kirk L Peterson; Wylie W Vale; Kuo-Fen Lee Journal: Proc Natl Acad Sci U S A Date: 2002-05-28 Impact factor: 11.205
Authors: Jan Heidemann; Hitoshi Ogawa; Michael B Dwinell; Parvaneh Rafiee; Christian Maaser; Henning R Gockel; Mary F Otterson; David M Ota; Norbert Lugering; Wolfram Domschke; David G Binion Journal: J Biol Chem Date: 2002-12-20 Impact factor: 5.157
Authors: Pauline M Anton; Jerome Gay; Andreas Mykoniatis; Amy Pan; Michael O'Brien; Daniel Brown; Katia Karalis; Charalabos Pothoulakis Journal: Proc Natl Acad Sci U S A Date: 2004-05-24 Impact factor: 11.205
Authors: Rina Plattner; Brenda J Irvin; Shuling Guo; Kevin Blackburn; Andrius Kazlauskas; Robert T Abraham; John D York; Ann Marie Pendergast Journal: Nat Cell Biol Date: 2003-04 Impact factor: 28.824
Authors: Ivy Ka Man Law; David Miguel Padua; Dimitrios Iliopoulos; Charalabos Pothoulakis Journal: Am J Physiol Gastrointest Liver Physiol Date: 2017-08-03 Impact factor: 4.052
Authors: Eric Kubat; Shilpi Mahajan; Min Liao; Larry Ackerman; Peter T Ohara; Eileen F Grady; Aditi Bhargava Journal: Mol Med Date: 2013-07-24 Impact factor: 6.354
Authors: Andrzej T Slominski; Michal A Zmijewski; Blazej Zbytek; Desmond J Tobin; Theoharis C Theoharides; Jean Rivier Journal: Endocr Rev Date: 2013-08-12 Impact factor: 19.871
Authors: Alicia Arranz; Maria Venihaki; Berber Mol; Ariadne Androulidaki; Erini Dermitzaki; Olga Rassouli; Jorge Ripoll; Efstathios N Stathopoulos; Rosa P Gomariz; Andrew N Margioris; Christos Tsatsanis Journal: Mol Cancer Date: 2010-09-27 Impact factor: 27.401